University of Washington researchers have engineered proteins with autonomous decision-making capabilities that respond to multiple biological cues, enabling ultra-precise drug targeting. This synthetic biology advance allows therapies to activate only when specific biomarker combinations are present, potentially reducing side effects and dosage requirements. The breakthrough leverages Boolean logic circuits and scalable biomanufacturing techniques that cut production time from months to weeks.